Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 05:59 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy
NCT00895245 · University of Washington · PHASE2 · terminated · last registry update 2017-05-18 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study stopped due to lack of efficacy in first 6 patients” | – | Registry record, University of Washington |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TACR1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2018-05-04Results posted on the registry: St. Louis University, Fosaprepitant (NCT01874119)
- 2018-04-12Results posted on the registry: Gynecologic Oncology Group, Aprepitant + Carboplatin (NCT01275664)
- 2018-03-08Results posted on the registry: Merck Sharp & Dohme LLC, Fosaprepitant + Placebo for fosaprepitant (NCT02519842)
- 2018-01-19Phase 3 first posted: Helsinn Healthcare SA, fosnetupitant/ palonosetron + netupitant/palonosetron (NCT03403712)
- 2017-12-08Phase 3 first posted: University of Rochester NCORP Research Base, Dexamethasone + Netupitant/Palonosetron Hydrochloride (NCT03367572)
- 2017-11-21Results posted on the registry: Merck Sharp & Dohme LLC, Fosaprepitant + Fosaprepitant Placebo (NCT01697579)
- 2017-11-17Also stopped (terminated): University of Southern California, granisetron transdermal system + fosaprepitant dimeglumine (NCT01649258)
- 2017-09-06Results posted on the registry: Merck Sharp & Dohme LLC, Aprepitant + Placebo to Aprepitant (NCT01732458)
- 2017-08-30Results posted on the registry: Yale University, Folfirinox (NCT01523457)
- 2017-08-02Results posted on the registry: The Scripps Research Institute, aprepitant + Placebo (NCT02210195)
- 2017-07-17Phase 3 first posted: All India Institute of Medical Sciences, Ondansetron + Dexamethasone (NCT03219710)
- 2017-05-10Results posted on the registry: Vanderbilt University Medical Center, Aprepitant + Placebo (NCT01625455)
- 2017-05-10Also stopped (terminated): Vanderbilt University Medical Center, Aprepitant + Placebo (NCT01625455)
- 2017-05-09Also stopped (terminated): OHSU Knight Cancer Institute, fosaprepitant dimeglumine + systemic chemotherapy (NCT01031953)
- 2017-04-25Results posted on the registry: Kyungpook National University Hospital, aprepitant + palonosetron (NCT02597907)
- 2017-04-19Also stopped (terminated): The Hospital for Sick Children, Oral Aprepitant + Aprepitant (NCT01249001)
- 2017-04-10Results posted on the registry: Alliance for Clinical Trials in Oncology, Olanzapine + Chemotherapy (cisplatin or cyclophosphamide and doxorubicin) (NCT02116530)
- 2017-03-30Results posted on the registry: First Affiliated Hospital of Harbin Medical University, Olanzapine + Aprepitant (NCT02484911)
- 2017-03-30Results posted on the registry: Indiana University, Olanzapine + Aprepitant (NCT02097823)
- 2017-03-28Also stopped (terminated): University of Southern California, Aprepitant + Dexamethasone (NCT02550119)
- 2017-03-27Results posted on the registry: The Scripps Research Institute, Aprepitant + Placebo (NCT01611948)
- 2017-03-14Phase 3 first posted: CCTU, Experimental drug: Aprepitant + Experimental drug: Ondansetron (NCT03079219)
- 2017-03-09Results posted on the registry: University of Kansas Medical Center, Palonosetron + Aprepitant (NCT00600353)
- 2017-02-02Phase 3 first posted: M.D. Anderson Cancer Center, Netupitant + Palonosetron (NCT03040726)
- 2016-12-28Results posted on the registry: Heron Therapeutics, APF530 + Ondansetron (NCT02106494)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision